Retatrutide, developed by Soma Pharmaceuticals , represents a promising development in weight regulation. This innovative drug combines GLP-1 receptor function with GIP receptor stimulation , indicating impressive potential in clinical studies for body loss . Researchers believe the drug is expected to offer a different option for people struggling